Protagonist Therapeutics PTGX
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Protagonist Therapeutics (PTGX) Core Market Data and Business Metrics
Latest Closing Price
$46.88Price-Earnings Ratio
17.11Total Outstanding Shares
61.38 Million SharesDividend
No dividendSIC Description
Pharmaceutical PreparationsPrimary Exchange
NASDAQHeadquarters
7707 Gateway Blvd., Suite 140, Newark, CA, 94560-1160
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 2,061,341 Shares | 2.49 | 3/14/2025 | 5,129,814 Shares |
| 848,244 Shares | 5.74 | 2/28/2025 | 4,865,114 Shares |
| 551,115 Shares | 7.66 | 2/14/2025 | 4,221,220 Shares |
| 496,389 Shares | 7.64 | 1/31/2025 | 3,793,117 Shares |
| 611,813 Shares | 6 | 1/15/2025 | 3,670,399 Shares |
| 690,804 Shares | 5.5 | 12/31/2024 | 3,798,682 Shares |
Cash Flow Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities | $22.35 Million |
| Net Cash Flow From Financing Activities, Continuing | $22.35 Million |
| Net Cash Flow, Continuing | $-99.41 Million |
| Net Cash Flow From Operating Activities | $230.29 Million |
| Net Cash Flow | $-99.41 Million |
| Net Cash Flow From Investing Activities, Continuing | $-352.05 Million |
Income Statement
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Net Income/Loss Attributable To Noncontrolling Interest | $0 |
| Preferred Stock Dividends And Other Adjustments | $0 |
| Income/Loss From Continuing Operations After Tax | $170.85 Million |
| Basic Average Shares | $62.53 Million |
| Income/Loss From Continuing Operations Before Tax | $173.08 Million |
| Diluted Average Shares | $65.83 Million |
Comprehensive Income
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Parent | $172.35 Million |
| Other Comprehensive Income/Loss Attributable To Parent | $1.51 Million |
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $172.35 Million |
| Other Comprehensive Income/Loss | $-62.32 Million |
Balance Sheet
October 1, 2023 to September 30, 2024
| Metric | Value |
|---|---|
| Noncurrent Assets | $127.09 Million |
| Liabilities | $71.94 Million |
| Assets | $603.86 Million |
| Noncurrent Liabilities | $27.36 Million |
| Equity | $531.91 Million |
| Liabilities And Equity | $603.86 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||